Structure Therapeutics Q2 net loss widens on higher R&D costs
GPCR•Outlook
Company expects cash reserves to fund operations and key clinical milestones through end of 2028.
Topline 72-week aleniglipron ACCESS OLE data is expected in Q3 2026.
Company plans to initiate a combination GLP-1 and amylin receptor agonist clinical trial in Q4 2026.
Analyst coverage
- The current average analyst rating on the shares is buy and the breakdown of recommendations is 16 strong buy or buy, 1 hold and no sell or strong sell.
- The average consensus recommendation for the biotechnology & medical research peer group is buy.
- Wall Street's median 12-month price target for Structure Therapeutics Inc. is $101.00, about 99.9% above its August 5 closing price of $50.53.
Result drivers and key details
- Clinical trial costs — Company said higher R&D expenses were mainly due to increased clinical trial activity, preclinical research, and personnel costs.
